Hypokalemic periodic paralysis as first sign of thyrotoxicosis

Trifanescu RA* **, Danciulescu Miulescu R*, Carsote M*, Poiana C* **
*Department of Endocrinology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
**C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania

Correspondence to: Catalina Poiana, MD, PhD, Associate Professor of Endocrinology, Endocrinology Department, “Carol Davila” University of Medicine and Pharmacy, 34-36 Aviatorilor Blvd., code 011863, Bucharest, Romania, Phone/Fax: + 4021 317 7430; E-mail: endoparhon@gmail.com

Received: November 10th, 2012 – Accepted: January 14th, 2013

Abstract

Background: periodic paralysis related to hypokalemia is seldom reported in thyrotoxicosis, and it usually occurs in Asian males.

Patients and methods: Two Romanian (Caucasian) young patients presented with hypokalemic paralysis. TSH, FT4, TT3 was measured by immunochemiluminescence.

Case report 1. Patient O.R., aged 19, presented marked asthenia and lower limbs paralysis, following high carbohydrate meal. He declared 10 kg weight loss on hypocaloric diet and mild sweating. Biochemical data revealed moderate hypokalemia (K+=2.6 mmol/L) and thyrotoxicosis (TSH<0.03 mIU/L, FT4=30 pmol/L, TT3=315 ng/dL).

Case report 2. Patient T.A., aged 18, presented 2 episodes of weakness and flaccid paralysis, with hypokalemia, precipitated by effort, without any sign of thyrotoxicosis. Biochemical data revealed severe hypokalemia (K+=1.8 mmol/L) and thyrotoxicosis (TSH<0.03 mIU/L, FT4=24 pmol/L, TT3=190 ng/dL). Treatment with intravenous potassium, thereafter methimazole and propranolol were administered in both cases, with the maintenance of normal kalemia and thyrotoxicosis' control.

Conclusion: these 2 cases of hypokalemic periodic paralysis occurring in young Caucasian teenagers with mild thyrotoxicosis underlined the importance of thyroid screening in patients with symptomatic hypokalemia, even in the absence of symptoms and signs of thyrotoxicosis.

Keywords: hypokalemic paralysis, thyrotoxicosis, teenagers

Abbreviations:
THPP=Thyrotoxic periodic paralysis, BMI=body mass index, TRAb=TSH receptor antibody, ECG=electrocardiogram.

Introduction

Hypokalemia with acute paralysis is a medical emergency. Up to 43.3% of the patients with hypokalemic paralysis had a secondary cause, 16.6-32% showing thyrotoxic paralysis [1,2].

Thyrotoxic periodic paralysis (THPP) is an unusual complication of thyrotoxicosis, that manifests as acute episodes of muscle weakness associated with hypokalemia [3,4]. The disease primarily affects people of Asian descent, but also other ethnic groups [5] such as Europeans [6], Hispanics [7], native Americans [8]. THPP predominantly affects males [3,9].

THPP was reported more frequently in Graves disease [10], but also in toxic multinodular goiter [11], toxic thyroid adenoma [12], TSH secreting pituitary adenomas [13], painless thyroiditis [14], in patients with Jodbasedow thyrotoxicosis [15] and in patients taking levothyroxine [16].

Patients and methods

Two young, non-consanguineous Caucasian patients (18 and 19 years) initially presented with periodic hypokalemic paralysis. They did not have Asian ancestors, or a familial history of periodic paralysis, or personal history of distal renal tubular acidosis, primary hyperaldosteronism or Bartter-like syndrome. Both patients denied diarrhea, diuretics, licorice or alcohol use.

TSH, FT4, TT4, TT3 were measured by immunochemiluminescence, upright aldosterone by ELISA, plasma 8 a.m. cortisol and direct rennin by immunochemiluminescence.

Case reports

Case 1, O.R., male, aged 19, overweight (BMI=27.8 kg/m2), presented with marked asthenia and lower limbs paralysis. The symptoms had abrupt
onset in the morning, after a rich carbohydrate meal. The patient declared 10 kg weight loss on hypocaloric diet and mild sweating. Neurological exam showed symmetrical, lower limbs flaccid paresis. Biochemical assessment revealed hyperglycemia (126 mg/dL) and moderate hypokalemia (2.6 mmol/L). Intravenous potassium supplements were administered with normalization of serum potassium levels. In the endocrine department, the physical exam revealed mild tachycardia, small diffuse goiter and tremor, without exophthalmia. Hormonal assessment revealed thyrotoxicosis (TSH<0.03 mIU/L, FT4=30.6 pmol/L, TT3=315 ng/dL); TSH receptor antibodies (TRAb) were positive (Table 1). Oral glucose tolerance test was normal. After restoration of normal serum potassium levels, potassium excretion was normal (31.6 mmoL/24 hours).

Case 2, T. A., male, aged 18, presented with marked asthenia and quadriplegia with abrupt onset after an intensive physical effort. Neurological exam showed flaccid limbs paralysis. Severe hypokalemia (1.8 mmol/L) was present. Intravenous potassium supplements were administered with normalization of serum potassium levels. In the endocrine department, physical exam revealed small diffuse goiter without tachycardia, tremor or exophthalmia. Hormonal assessment revealed mild thyrotoxicosis (TSH<0.03 mIU/L, FT4=24 pmol/L, TT3=190 ng/dL) (Table 1). After the restoration of normal serum potassium levels, renal potassium excretion was normal (51.8 mmoL/24 hours).

In both patients, thyroid ultrasound revealed hypoechoic, diffuse goiter; there were no signs of hypercortisolism and adrenal assessment was normal (Table 1).

Table 1. Clinical and biochemical features at the onset of hypokalemic paralysis

| symptoms                  | Case 1                        | Case 2                        |
|---------------------------|-------------------------------|-------------------------------|
| Marked asthenia           | Lower limbs paralysis         | Muscle weakness               |
| Physical effort           |                               | Flaccid quadriplegia          |
| Hyperglycaemia (126 mg/dL)| Physical effort               |
| 27.8                      |                               |                               |
| 2.6                       |                               |                               |
| 143                       |                               |                               |
| 0.03                      |                               |                               |
| 30.6                      |                               |                               |
| 315                       |                               |                               |
| Hypoechoic, diffuse goiter | Diffuse goiter                |
| 0.87                      |                               |                               |
| 0.57                      |                               |                               |
| Normal ultrasound         |                               | Normal CT scan                |

Antithyroid drugs (Methimazole 30 → 20 → 10 → 5 mg/day) and non-selective β blockers (Propranolol 120 → 60 → 40 → 30 mg/day) treatment were administered in both patients, with long-term maintenance of normal serum potassium levels and progressive normalization of TSH and FT4 levels (Table 2). Antithyroid drugs’ treatment duration was of 18 months. No recurrence of the paralysis has been noted during follow-up.

Table 2. Biochemical data after 3 months treatment with antithyroid drugs and non-selective β blockers

|                        | Case 1 | Case 2 |
|------------------------|--------|--------|
| K+(mmol/L)             | 4.5    | 5      |
| TSH(mIU/L)             | 0.3    | 0.09   |
| FT4(pmol/L)            | 14     | 12.6   |

To our knowledge, these cases are the first Romanian published cases of hypokalemic thyrotoxic paralysis so far.

Discussion

Both our patients are males. THPP had a higher predilection for men than for women [4]. The disease occurred especially in young adults [17].
Both our patients showed mild thyrotoxicosis. Many affected patients do not have obvious symptoms and signs of thyrotoxicosis [3,22]. Both patients showed sinus tachycardia, U waves, without ventricular arrhythmia on electrocardiogram (ECG). ECG manifestations in THPP were slightly different as compared with non-thyrotoxic periodic paralysis, at similar low K⁺ levels: heart rate, PR interval, and QRS voltage were significantly higher [23]. Young patients with THPP complicated by acute hypercapnic respiratory failure and ventricular tachycardia [22] or with thyroid storm, psychosis and episodic acute respiratory failure [5] were reported.

The underlying mechanism of THPP is an acute extra to intracellular shift of potassium, mainly into the muscles, due to the stimulation of the activity of the Na-K-ATPase pump by thyroid hormones, via beta-adrenergic stimulation [3]. Genetic predisposition plays a role in the pathogenesis of thyrotoxic hypokalemic periodic paralysis; polymorphisms of the calcium channel alpha1-subunit gene [24], mutations in SCN4A or CACNA1S [25] were reported. Up to 33% of THPP patients showed a mutation in Kir2.6 gene, regulated by thyroid hormones [26]. Single nucleotide polymorphisms of gamma-aminobutyric acid receptor alpha3 subunit were associated with THPP [27].

Treatment of THPP implies two steps: the hypokalemia correction and the euthyroidism restoring [4]. Both our patients initially received intravenous potassium chloride supplementation; correction of hypokalemia by potassium supplementation, in order to avoid fatal cardiac arrhythmias and to reverse muscle weakness is mandatory [28,3]. However, the patients do not have a total body deficiency of potassium, so aggressive potassium supplementation should be avoided, because it can result in rebound hypokalemia [29]. Potassium supplementation should be given as small as possible (<10 mmol/hr) [28]. Intravenous glucose solution should be avoided, because it could aggravate hypokalemia, leading to death [30]. The second step is the treatment with antithyroid drugs and beta-blockers. Nonselective beta-adrenergic blockers can ameliorate and prevent recurrence of the paralytic attacks. Both our cases received propranolol 120 mg/day and antithyroid drugs.

In both presented cases, no recurrence of the paralysis has been noted within the first 3 years after diagnosis. However, before achieving the euthyroid status, the rate of recurrent attacks could be up to 62.2% [17]. This episodic paralysis will remit with definitive control of hyperthyroidism [3]. Both our patients refused definitive surgical treatment of thyrotoxicosis and underwent regular thyroid follow-up.

Conclusion

Thyrotoxic hypokalemic periodic paralysis, although rare in Caucasian men, should be considered in the differential diagnosis of hypokalemic paralysis. Thyroid screening is mandatory in patients with muscular paralysis associated with hypokalemia.

References

1. Maurya PK, Kalita J, Misra UK. 6. Spectrum of hypokalaemic periodic paralysis in a tertiary care centre in India. Postgrad Med J. 2010; 86: 692-695.
2. Phukdeekecharoen B, Ruangraksa C, 7. Radinahamed P. Hypokalaemia and paralysis in the Thai population. Nephrol Dial Transplant. 2004; 19: 2013-2016.
3. Kung AW. Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge. J Clin Endocrinol Metab. 2006; 91: 2490-2495.
4. Pothiwa L, Levine SN. Analytic review: thyrotoxic periodic paralysis: a review. J Intensive Care Med. 2010; 25: 71-77.
5. Abbasi B, Sharif Z, Sprabery LR. Hypokalemic thyrotoxic periodic paralysis with thyrotoxic psychosis and hypercapnic respiratory failure. Am J Med Sci. 2010; 340: 147-153.
6. Barahona MJ, Vinagre I, Sojo L, Cubero JM, Perez A. Thyrotoxic periodic paralysis: a case report and literature review. Clin Med Res. 2009; 7: 96-98.
7. Zumod LA, Terzian C, Brannan T. Thyrotoxic hypokalemic periodic paralysis in a Hispanic male. J Natl Med Assoc. 2002; 94: 363-366.
8. Seshadri P, Frank KD, Iqbal N. Thyrotoxic hypokalemic periodic paralysis in a Native American patient: case report and literature review. Endocr Pract. 2002; 8: 362-363.
9. Mellgren G, Bleskastad IH, Aanderud S, Zumo LA, Terzian C, Brannan T, Barahona MJ, Vinagre I, Sojo L, Cubero JM, Perez A. Thyrotoxic periodic paralysis: a case report and literature review. Endocr Pract. 2002; 8: 362-363.
10. Erem C. Thyrotoxic hypokalemic periodic paralysis in a Turkish male with graves' disease: a rare case report and review of the literature. Endocrine. 2005; 27: 63-65.
11. Arenas Gracia M, Mata MB, Serrano Corredor MS, Calduch Brosa JV, Martinez L, V, Segarra Soria MM. Lymphocytic colitis: hypopotassemia as a complication and an association with toxic multinodular goiter. Gastroenterol Hepatol. 2000; 23: 75-78.
12. Tagami T, Usui T, Shimatsu A, Naruse M. Toxic thyroid adenoma presenting as hypokalemic periodic paralysis. Endocr J. 2007; 54: 797-803.
13. Papp N, Papanastasiou L, Markou A, Androulakis I, Kontogeorgos G, Seretis A, Piaditis G. Thyrotoxic periodic paralysis as the first manifestation of a thyrotropin-secreting pituitary adenoma. Hormones. 2010; 9: 82-86.
14. Oh SB, Ahn J, Oh MY, Choi BG, Kang JH, Jeon YK, Kim SS, Kim BH, Kim YK, Kim IJ. Thyrotoxic periodic paralysis associated with transient thyrotoxicosis due to painless thyroiditis. J Korean Med Sci. 2012; 27: 822-829.

15. Kane MP, Busch RS. Drug-induced thyrotoxic periodic paralysis. Ann Pharmacother. 2006; 40: 777-781.

16. Chen YC, Fang JT, Chang CT, Chou HH. Thyrotoxic periodic paralysis in a patient abusing thyroxine for weight reduction. Ren Fail. 2001; 23: 139-142.

17. Hsieh MJ, Lyu RK, Chang WN, Chang KH, Chen CM, Chang HS, Wu YR, Chen ST, Ro LS. Hypocalcemic thyrotoxic periodic paralysis: clinical characteristics and predictors of recurrent paralytic attacks. Eur J Neurol. 2008; 15: 559-564.

18. Goh SH. Thyrotoxic periodic paralysis: reports of seven patients presenting with weakness in an Asian emergency department. Emerg Med J. 2002; 19: 78-79.

19. Reisin RC, Martinez O, Moran M, Rovira M, Roccatagliata G, Pardal A, de la Balze AE. Thyrotoxic periodic paralysis in caucasiains. Report of 8 cases. Neurologia. 2000; 15: 222-225.

20. Yu TS, Tseng CF, Chuang YY, Yeung LK, Lu KC. Potassium chloride supplementation alone may not improve hypokalemia in thyrotoxic hypokalemic periodic paralysis. J Emerg Med. 2007; 32: 263-265.

21. El-Hennawy AS, Nesa M, Mahmoud AK. Thyrotoxic hypokalemic periodic paralysis triggered by high carbohydrate diet. Am J Ther. 2007; 14: 499-501.

22. Wu CZ, Wu YK, Lin JD, Kuo SW. Thyrotoxic periodic paralysis complicated by acute hypercapnic respiratory failure and ventricular tachycardia. Thyroid. 2008; 18: 1321-1324.

23. Hsu YJ, Lin YF, Chau T, Liou JT, Kuo SW, Lin SH. Electrocardiographic manifestations in patients with thyrotoxic periodic paralysis. Am J Med Sci. 2003; 326: 128-132.

24. Kung AW, Lau KS, Fong GC, Chan V. Association of novel single nucleotide polymorphisms in the calcium channel alpha 1 subunit gene (Ca(v)1.1) and thyrotoxic periodic paralysis. J Clin Endocrinol Metab. 2004; 89: 1340-1345.

25. Raja Rayan DL, Hanna MG. Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis. Curr Opin Neurol. 2010; 23: 466-476.

26. Ryan DP, da Silva MR, Soong TW, Fontaine B, Donaldson MR, Kung AW, Jongjaroenprasert W, Liang MC, Khoo DH, Cheah JS, Ho SC, Bernstein HS, Maciel RM, Brown RH Jr, Ptacek LJ. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell. 2010; 140: 88-98.

27. Jongjaroenprasert W, Chanprapertytlin S, Butaderj S, Nakasatien S, Charatcharoenwitthaya N, Himathongkam T, Ongphiphadhanakul B. Association of genetic variants in GABRA3 gene and thyrotoxic hypokalemic periodic paralysis in Thai population. Clin Endocrinol. 2008; 68: 646-651.

28. Lu KC, Hsu YJ, Chiu JS, Hsu YD, Lin SH. Effects of potassium supplementation on the recovery of thyrotoxic periodic paralysis. Am J Emerg Med. 2004; 22: 544-547.

29. Chou HK, Tsao YT, Lin SH. An unusual cause of thyrotoxic periodic paralysis: triiodothyronine-containing weight reducing agents. Am J Med Sci. 2009; 337: 71-73.

30. Chen DY, Schneider PF, Zhang XS, He ZM, Chen TH. Fatality after cardiac arrest in thyrotoxic periodic paralysis due to profound hypokalemia resulting from intravenous glucose administration and inadequate potassium replacement. Thyroid. 2012; 22: 969-972.